Videos

Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), discusses ways to address burnout in the hematology/oncology space.

Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), provides details of the upcoming HOPA 2022 conference.

Elizabeth Spurlock, MA, PHR, director of HR Business Partner at Texas Oncology, discusses how burnout among physicians, nurses, and hospital administrators has impacted the role of the pharmacist in patient care.

Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), provides details of the upcoming HOPA 2022 conference.

Pharmacy Times spoke with students at the Idaho State University College of Pharmacy and its partner program at the University of Alaska Anchorage College of Health.

Lisa Nodzon, PhD, ARNP, AOCNP; Katie Tobon, PharmD, BCOP; and Javier Pinilla-Ibarz, MD, PhD, share insight on strategies for the monitoring and management of BTK inhibitor–associated toxicities in CLL and review the importance of a multidisciplinary approach to treatment.

Students from the University of the Sciences Philadelphia College of Pharmacy and the Rutgers University Ernest Mario School of Pharmacy went head-to-head to answer questions about the pharmacy field.

Larry Buie, PharmD, BCOP, FASHP, outgoing president of the Hematology/Oncology Pharmacy Association (HOPA), shares some details of HOPA’s upcoming 2022 annual conference in Boston and provides an overview of his term as HOPA’s president.

Pharmacy Times spoke with students at the Idaho State University College of Pharmacy and its partner program at the University of Alaska Anchorage College of Health.

Study suggests a link between vitamin D deficiency and COVID-19 severity and mortality.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses how the understanding of malignant lymphomas’ pathobiology and relationship with the immune system evolved during her clinical and investigational research into the subject.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses how the field of hematopathology has changed over the last decade.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses next steps following the results of the phase 2 trial assessing niraparib on the treatment of patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the implications of the phase 2 trial assessing niraparib on the treatment of patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.

Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the advantages of including pharmacy staff as part of the care team when payer or drug availability challenges arise.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses her American Society for Investigative Pathology Gold-Headed Cane Award lecture at the Experimental Biology 2022 conference on the classification of lymphoma in the modern era.

Lisa Nodzon, PhD, ARNP, AOCNP, and Javier Pinilla-Ibarz, MD, PhD, evaluate novel agents and combinations in the pipeline for the management of CLL.

Jeffrey B. Simon, JD, co-chair of the National Opioid Litigation Conference, discusses some steps that pharmacists could take to help address the opioid epidemic in the pharmacy.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the endpoints of the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Darren Mensch, PharmD, BCPS, BCACP, clinical ambulatory care pharmacist of population health at Jefferson Health in Abington, describes the role pharmacists play in team-based care, population health management, and value-based care.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses how patients were selected for the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses how SGO shapes and guides the direction of medical researchers and health care professionals in the gynecologic oncology field.

Pharmacy Times spoke with Meagen Rosenthal, PhD, about her session at the APhA 2022 Annual Meeting and Exposition, titled "Heal Thyself: Burnout Recovery for Front-Line Heroes."

Jeffery Goad, PharmD, MPH, associate dean of Academic Affairs in School of Pharmacy at Chapman University discusses the future of pharmacy when it comes to immunizations.

Pharmacists are essential partners in solving overspending caused by dose-specific packaging of lenvatinib.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the design of the phase 2 trial assessing niraparib in patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses the future of the pharmacist on the gynecologic oncology patient care team.

Daniel Krinsky, MS, owner and president of EduCare4U and PGx101, and Stefanie Ferreri, PharmD, Smith and Olsen Distinguished professor at the Eshelman School of Pharmacy in the University of North Carolina, discuss the additions, removals, and changed to OTC products in the past 2 years.

Pharmacy Times spoke to Susan Cornell, BS, PharmD, CDCES, FAPhA, FADCES, about her session she presented at the APhA 2022 Annual Meeting and Exposition, titled "Know the Facts: Annual Diabetes Update."

Lenvatinib was approved in July of 2021 for the treatment of microsatellite-stable advanced endometrial cancer after platinum-based chemotherapy.